The intricate balance of the human immune system frequently undergoes significant recalibration with advancing age, often leading to a state of chronic dysregulation. This profound shift, commonly termed immunosenescence, renders older individuals particularly susceptible to severe health complications, including life-threatening systemic infections like sepsis, and contributes to a spectrum of age-related diseases characterized by persistent inflammation. Recent groundbreaking investigations conducted by a research collective at the University of Minnesota have now elucidated a critical molecular pathway underpinning this age-related immunological decline, specifically focusing on how a particular type of immune cell, known as a macrophage, becomes perpetually entrenched in an inflammatory state as organisms age. These pivotal findings, detailing an internal feedback loop driving cellular inflammation, were formally presented in the esteemed scientific journal Nature Aging.
At the heart of this discovery lies a protein designated GDF3, or Growth Differentiation Factor 3. Researchers observed that as macrophages mature within an aging biological system, they begin to excessively synthesize and secrete GDF3. Crucially, this protein does not merely act on distant cells; it establishes an autocrine signaling loop, meaning it feeds back directly onto the very macrophages that produced it. This self-reinforcing mechanism serves to amplify and sustain the inflammatory activity within these cells, effectively locking them into a heightened pro-inflammatory phenotype. This persistent cellular agitation then exacerbates the body’s overall inflammatory response, particularly during acute challenges like bacterial infections, thereby worsening outcomes in conditions such as sepsis, where a tightly controlled immune reaction is paramount for survival.
The meticulous work, spearheaded by biochemistry graduate student In Hwa Jang, delved into the specific molecular machinery through which GDF3 exerts its influence. The team identified that GDF3 signaling primarily operates via the SMAD2/3 pathway, a well-established cascade involved in regulating cellular growth, differentiation, and immune responses. Activation of this pathway by GDF3 was found to induce profound and enduring alterations to the macrophage’s genome. These genomic modifications are not necessarily changes to the DNA sequence itself, but rather epigenetic alterations – stable changes in gene expression that do not involve changes to the underlying DNA code. These epigenetic shifts fundamentally reprogram the macrophages, causing them to consistently overproduce and release an elevated repertoire of inflammatory cytokines, which are small proteins critical for cell signaling that mediate and regulate immunity and inflammation. This sustained release of pro-inflammatory mediators contributes significantly to the systemic inflammation observed in aging individuals.
The implications of this finding are substantial, offering a novel perspective on the mechanisms driving "inflammaging" – the low-grade, chronic systemic inflammation that characterizes aging and contributes to a myriad of age-related pathologies, from cardiovascular disease to neurodegeneration. Christina Camell, PhD, an associate professor jointly affiliated with the University of Minnesota Medical School and College of Biological Sciences, underscored the significance of their work, stating, "Macrophages are indispensable regulators in the initiation and progression of inflammatory processes throughout the body. Our investigation has precisely pinpointed a previously unrecognized pathway that these cells exploit to perpetuate their inflammatory status in an aged context." Dr. Camell further emphasized the translational potential, noting, "These compelling results strongly suggest that therapeutically targeting or interrupting this specific pathway could represent a viable strategy to mitigate the exacerbated inflammation that so often compromises organ function in older adults. This discovery offers a promising avenue for the development of future interventions aimed at tempering detrimental inflammatory responses."
To validate their hypotheses, the research team conducted a series of sophisticated experiments. In one critical set of studies, they genetically engineered preclinical models – typically laboratory animals such as mice – to lack the GDF3 gene. The deletion of GDF3 resulted in a marked reduction in the harmful inflammatory responses typically observed following exposure to bacterial toxins, providing compelling evidence of GDF3’s central role in driving inflammation. Expanding on this, the scientists also investigated pharmacological interventions. They administered compounds designed to inhibit the GDF3-SMAD2/3 signaling pathway to older preclinical models. Encouragingly, these interventions not only modulated the behavior of inflammatory macrophages found in adipose (fat) tissue – a known hub of age-related inflammation – but also dramatically improved survival rates in these aged models when subsequently exposed to severe infectious challenges. This demonstrates a direct link between pathway modulation and improved clinical outcomes in a relevant biological context.
Further reinforcing the clinical relevance of their laboratory findings, the Minnesota team collaborated with Dr. Pamela Lutsey from the University’s School of Public Health. Through a comprehensive analysis of human health data drawn from the extensive Atherosclerosis Risk in Communities Study (ARIC) – a longitudinal observational study investigating the causes of atherosclerosis and its clinical outcomes – they established a significant correlation. The analysis revealed that elevated levels of GDF3 in older human subjects were indeed associated with heightened markers of inflammatory signaling, thus bridging the gap between their experimental models and human physiology and underscoring the potential applicability of their discoveries to human health.
The scientific journey, however, is rarely complete with a single discovery. The researchers acknowledge that substantial further investigation is imperative to fully delineate the intricate molecular components operating within this newly identified pathway. Precisely understanding how it regulates specific inflammatory signals will be crucial for developing highly targeted and effective therapeutic strategies. Building upon the robust foundation of these initial findings, Dr. Camell has recently been honored with a prestigious 2025 AFAR Discovery Award from the American Federation for Aging Research. This significant funding will enable her team to pursue additional studies, specifically exploring how these pro-inflammatory macrophages influence the function and health of multiple metabolic organs – such as the liver, pancreas, and muscles – and, by extension, impact overall metabolic healthspan, a measure of the duration of an individual’s healthy life free from metabolic diseases.
Such ambitious and impactful research endeavors are made possible through the critical support of various funding bodies. This particular study benefited from substantial backing from several institutes within the National Institutes of Health (NIH), including grants F99AG095479, R00AG058800, R01AG069819, and R01AG079913, reflecting its significance to aging research. Additional support was provided by the McKnight Land-Grant Professorship, the Glenn Foundation for Medical Research in conjunction with the AFAR 2025 Discovery Award, the Diana Jacobs Kalman/AFAR Scholarships for Research in the Biology of Aging, and the Medical Discovery Team on the Biology of Aging. The Atherosclerosis Risk in Communities Study, a cornerstone of public health research, receives its funding, in whole or in part, from federal sources, primarily the National Heart, Lung, and Blood Institute (NHLBI) under various contracts. The advanced SomaScan assays utilized for the ARIC data analysis were conducted by SomaLogic Inc., in a collaborative arrangement that facilitated the exchange for use of ARIC data, with additional support from NIH/NHLBI grant R01 HL134320. This extensive network of support underscores the collaborative and interdisciplinary nature of modern biomedical research aimed at addressing complex challenges like age-related inflammation and its profound impact on human health and longevity. The identification of GDF3 and its signaling pathway as a driver of chronic inflammation in aging offers a beacon of hope for developing new strategies to promote healthier aging and enhance resilience against diseases that disproportionately affect the elderly population.
About the Author
